<DOC>
	<DOCNO>NCT00551122</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine , paclitaxel , ifosfamide , cisplatin , work different way stop tumor cell divide stop grow die . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose gemcitabine give together paclitaxel , ifosfamide , cisplatin , see well work treat patient progressive relapse metastatic germ cell tumor .</brief_summary>
	<brief_title>Gemcitabine , Paclitaxel , Ifosfamide , Cisplatin Treating Patients With Progressive Relapsed Metastatic Germ Cell Tumors</brief_title>
	<detailed_description>OBJECTIVES : - To determine maximum tolerate dose ( MTD ) gemcitabine hydrochloride administer TIP chemotherapy comprise paclitaxel , ifosfamide , cisplatin growth factor support ( Gem-TIP ) patient progressive relapse metastatic germ cell tumor . - To compare MTD Gem-TIP regimen MTD determine previous Medical Research Council study TIP alone . - To compare degree dose intensification achieve Gem-TIP chemotherapy achieve prior study TIP chemotherapy alone . - To assess dose gemcitabine hydrochloride deliver TIP regimen patient . - To measure response rate failure-free survival patient treat Gem-TIP alone . - To assess utility PET scan Gem-TIP chemotherapy patient . OUTLINE : This multicenter , phase I dose-escalation study gemcitabine hydrochloride follow phase II study . - Phase I : Patients receive gemcitabine hydrochloride IV 30 minute paclitaxel IV 3 hour day 1 , cisplatin IV 4 hour day 1-5 , ifosfamide IV 1 hour day 2-6 . Patients also receive filgrastim lenograstim ( G-CSF ) subcutaneously ( SC ) day 7-18 blood count recover OR pegfilgrastim SC day 6 . Treatment repeat every 3 week 4 course absence disease progression unacceptable toxicity . - Phase II : An additional cohort 14 patient treated phase I MTD determine phase I . After completion study therapy , patient follow periodically 1 year investigator 's discretion .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Meets follow criterion : Histologically confirm extracranial primary germ cell cancer , seminoma , nonseminoma Unresectable metastatic disease No completely resect cancer Rising serum marker ( i.e. , alphafetoprotein human chorionic gonadotropin ) sequential measurement biopsyproven unresectable germ cell cancer In first relapse single prior cisplatincontaining combination chemotherapy Patients late relapse ( i.e. , &gt; 2 year post initial chemotherapy ) consider surgery rather chemotherapy , technically feasible No patient cerebral metastasis alone Progressive cerebral systemic disease may consider study , provide cranial irradiation also consider component care PATIENT CHARACTERISTICS : Medically psychologically fit receive intensive chemotherapy schedule WBC &gt; 3.5 time 10^9/L Platelet count &gt; 130 time 10^9/L Glomerular filtration rate â‰¥ 50 mL/min ( determined 24 hour creatinine clearance nuclear medicine technique ) Fertile patient must use effective contraception No prior malignancy except successfully treat nonmelanoma skin cancer superficial bladder cancer No prior allergic reaction cisplatin platinum compound PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>testicular seminoma</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>testicular choriocarcinoma seminoma</keyword>
	<keyword>testicular embryonal carcinoma seminoma</keyword>
	<keyword>testicular embryonal carcinoma teratoma seminoma</keyword>
	<keyword>testicular embryonal carcinoma yolk sac tumor seminoma</keyword>
	<keyword>testicular yolk sac tumor teratoma seminoma</keyword>
	<keyword>recurrent extragonadal non-seminomatous germ cell tumor</keyword>
	<keyword>recurrent extragonadal seminoma</keyword>
	<keyword>stage IV extragonadal non-seminomatous germ cell tumor</keyword>
	<keyword>stage IV extragonadal seminoma</keyword>
	<keyword>recurrent extragonadal germ cell tumor</keyword>
	<keyword>ovarian mixed germ cell tumor</keyword>
	<keyword>adult central nervous system germ cell tumor</keyword>
</DOC>